FDA Approvals, News & UpdatesLeukemiaNewsworthy
In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation.
FDA Approvals, News & UpdatesLiver CancerNewsworthy
Previously approved for thyroid cancer and kidney cancer, the FDA has recently approved Lenvima as the first treatment for patients with liver cancer.
FDA Approvals, News & UpdatesKidney CancerNewsworthy
The use of Opdivo with Yervoy is the first immunotherapy combination therapy approved by the FDA for patients with kidney cancer.
FDA Approvals, News & UpdatesNewsworthyProstate Cancer
On February 14, 2018, the FDA approved Erleada (apalutamide; from Janssen) for the treatment of patients with nonmetastatic, castration-resistant prostate cancer.
Breast CancerFDA Approvals, News & UpdatesNewsworthy
The CDK4/CDK6 inhibitor Verzenio received a new indication, for use alone or in combination with an aromatase inhibitor, as initial therapy in women with HR-positive, HER2-negative advanced or metastatic breast cancer.